The 5th Commercializing Flow Chemistry Summit marks a pivotal year, introducing a significant shift in content to address the evolving needs of the pharmaceutical manufacturing ind
As King’s College London (KCL) scientists are once more in the headlines – this time with new ‘plug and play’ drug delivery technology that could offer a
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.